Tekalign Wondimu

FDA investigator

Appears on 12 documents from 2021 to 2026, most often at sites in Virginia. Most often cites insanitary conditions (FDCA 501(a)(2)(A)).

12
Documents on file
5.3
Observations per 483
2021
First seen
2026
Most recent

What they cite most

From 63 observations

Activity by year

2021: 1, 2022: 2, 2023: 4, 2024: 1, 2025: 2, 2026: 2

Where

Virginia 4 · New York 2 · Canada 1 · Japan 1 · Maryland 1 · New Jersey 1

Is Tekalign Wondimu coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

12 documents, newest first
FirmOpen
483 Richmond VA Medical CenterMay 12, 2026 · Richmond, Virginia
483 Bora PharmaceuticalsMar 20, 2026 · Baltimore, Maryland
483 Sumitomo Pharma Co., Ltd. 1450, Yasuzuka-ChoAug 7, 2025 · Suzuka, Japan
483 STAQ Pharma of Ohio, LLCMay 16, 2025 · Columbus, Ohio
483 Annovex Pharma, Inc.Sep 6, 2024 · Lorton, Virginia
483 Vegewax Candleworx LtdOct 19, 2023 · Concord, Canada
483 Pine Pharmaceuticals, LLCSep 19, 2023 · Tonawanda, New York

About this profile

What does Tekalign Wondimu inspect?

Tekalign Wondimu appears on 12 documents on file covering 12 sites, most often in Virginia.

What do they cite most often?

FDCA 501(a)(2)(A) (insanitary conditions), followed by 21 CFR 211.113 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Tekalign Wondimu is dated May 12, 2026.

FDA Investigator Tekalign Wondimu: 483s & Inspections · FDA Intel